Empowering Innovation and Driving New Momentum: CBC Healthcare Infrastructure Platform Files IPO Prospectus

In 2024, the number of innovative medical devices approved in China reached 65, setting a new record. Meanwhile, the growth rate of exports for high-value medical consumables increased significantly; in the first three quarters, the export value of Chinese medical instruments and devices amounted to USD 35.34 billion, a year-on-year increase of 4.4%.

In the face of a challenging external environment and factors such as centralized volume-based procurement, innovative medical device enterprises urgently need effective empowerment and support. This will help companies progress steadily through every stage—from R&D incubation and commercialization to domestic scale-up and international market expansion—while jointly building a robust industry ecosystem.

On January 9, the “Kangqiao Innovation Empowerment Series – 2025 Kangqiao Qingpu Life Science Park Exchange Meeting,” hosted by the Kangqiao Medical and Health Industry Facility Platform, was successfully held.The exchange session, themed “Pooling Strength for Innovation and Empowering New Capabilities · Kangqiao Boosts the Revitalization of Business Formats,” attracted numerous representatives from innovative enterprises in the medical device and IVD sectors.The conference delved into key issues such as corporate scale expansion, commercialization pathways, and overseas market development, providing attendees with an efficient and open platform for dialogue to jointly explore the evolution of the industrial ecosystem and envision the future of the healthcare industry.

Technological innovation, market demand, policy guidance, and global expansion are the four key elements driving the development of the healthcare industry. However, people often overlook that progress and breakthroughs in any given sector also depend on its surrounding industrial ecosystem. For innovative enterprises, an innovation ecosystem with cluster advantages and strong synergistic effects can provide abundant resources, comprehensive services, and accelerated growth pathways, which are crucial for the development of medical innovation companies.

As a flagship project meticulously developed by the Kangqiao Medical and Health Industry Facilities Platform, the Shanghai Kangqiao Qingpu Life Science Park is located in the Qingpu Park of the National Zhangjiang High-Tech Zone. The park has completed 10 integrated industrial spaces, with a total gross floor area of approximately 110,000 square meters. Here, the Kangqiao Medical and Health Industry Facilities Platform has established a core hub for the life sciences industry in the Yangtze River Delta, gathering leading enterprises. With its superior business environment, comprehensive industrial support systems, and mature industrial ecosystem, it provides unique development opportunities for innovative medical device companies.

Chen Chen, Managing Director of Kangqiao Healthcare Industry Facility Platform

Chen Chen, Managing Director of the Kangqiao Medical and Health Industry Facilities Platformstated that the Shanghai Kangqiao Qingpu Life Science Park is a flagship project of the Kangqiao Medical and Health Industry Infrastructure Platform in Shanghai, providing full-lifecycle infrastructure solutions for life sciences enterprises. By leveraging the Kangqiao Medical and Health Industry Infrastructure Platform, tenant companies will become key members of the Kangqiao Capital Life Sciences Ecosystem and benefit from its empowerment, including:

The platform will assist enterprises in securing maximum support from both municipal and district-level local governments. In addition to applying for various forms of government subsidies and facilitating talent settlement, the platform will actively help medical companies accelerate the application process for various licenses and certifications.

C-Bridge Capital’s Ruiqiao Credit Fund (RBF) provides medium- to long-term non-dilutive debt financing for growing enterprises; its healthcare infrastructure platform offers alternative financing solutions for tenant fit-outs, significantly reducing upfront capital expenditures; furthermore, the platform maintains long-term partnerships with numerous banks and financial institutions, safeguarding corporate development through multi-dimensional support.

The platform adopts an innovative “industry + space + capital” model, providing not only high-quality physical infrastructure but also integrating Kangqiao’s extensive expertise in capital markets, industrial resources, corporate operations, and global expansion. By establishing connections with multinational pharmaceutical and medical device companies as well as leading domestic healthcare enterprises, the platform collaborates to drive business development and commercialization.

 Liu Menghan, Director of Business Development, Kangqiao Medical and Health Industry Facility Platform

Meanwhile, the Shanghai Kangqiao Qingpu Life Science Park is emerging as a core hub for the healthcare industry in the Yangtze River Delta region. The park boasts convenient transportation links: it is only 25 minutes from Hongqiao Transportation Hub, 40 minutes from Suzhou BioBay, and one hour from the Zhangjiang Hi-Tech Park life science core area.

The Yangtze River Delta Eco-Green Integrated Development Demonstration Zone, where the industrial park is located, serves as a key pilot project for the national strategy of integrated development in the Yangtze River Delta. In recent years, to promote innovative development in the biopharmaceutical industry, Qingpu District has established a “1+2+X” industrial layout and introduced supportive policies such as the Several Policies on Promoting High-Quality Development of the Biopharmaceutical Industry in Qingpu District and the Support Measures for Advancing the Development of Advanced Manufacturing in Qingpu District, thereby creating favorable conditions for the growth of enterprises in the biopharmaceutical and life health sectors.

At the exchange session, Zhang Ruizhi, Head of Business Development and Strategy at Dawn Medical Technologies (a Qiao Capital portfolio company), and Lin Zhiwei, Vice President of Qiao Capital, delivered themed presentations on the global expansion of Chinese-made medical devices, as well as the commercialization and M&A integration of innovative medical devices.

Dawn BD and Head of Strategy, Zhang Ruizhi

Zhang RuizhiIt was pointed out that over the past five to ten years, Chinese medical technology companies have launched a large number of high-quality products into the market, which not only reduced healthcare costs and increased product penetration rates but also successfully achieved localization of medical device products. In emerging markets such as Thailand and the Middle East, the current situation is similar to that in China more than a decade ago—penetration rates for certain high-value medical products are far lower than those in developed countries, leaving many patients without access to high-quality treatment.

Based on this, Dawn’s core objective is to serve as a partner and agent, assisting Chinese medical device companies in entering emerging markets. Zhang Ruizhi emphasized that startups must first clarify their product performance and market positioning to formulate appropriate pricing strategies and select suitable target markets. Secondly, companies need to reasonably allocate overseas investments and prioritize team operations based on their actual circumstances, including cash flow, intellectual property, and regulatory approvals. Furthermore, companies should carefully consider key issues such as market entry in overseas regions, distributor collaborations, and sales channel development to mitigate potential risks.

Lin Zhiwei, Vice President of FountainVest Partners

Lin Zhiwei, Vice President of C-Bridge CapitalIt was stated that, in the current environment, a company’s true value is reflected in its comprehensive strength and platform capabilities. This means that companies must integrate the entire industry chain, from R&D and design to mass production and commercialization, which has become an essential attribute for valuable enterprises in the future. Meanwhile, cost control has emerged as a core competitive advantage for medical device companies. A successful enterprise must not only focus on achieving rapid revenue growth and expanding profit margins but also possess a profound understanding and insight into the industry. Qiaokang Capital looks forward to partnering with entrepreneurs to build industry-leading companies, helping them secure a top-three position in their respective niche markets, and jointly driving industry development.

During the event, guests from Kangqiao and Qingpu Industrial Park, along with corporate executives, engaged in in-depth discussions on topics including park development and carrier functionality, pilot implementation of industrial policies, support for key industries, talent acquisition, empowerment for global expansion, and computing power support.

Participating companies believe that the Kangqiao Life Science Park has established a comprehensive infrastructure system and an ecosystem empowerment program, with well-developed supporting facilities across various specialized sectors, thereby creating a cluster effect characterized by diversified innovation and collaborative development. Kangqiao Capital and its healthcare industry facility platform not only provide abundant alternative financing solutions, government relations support, domestic and international commercialization partnerships, talent resources, and public innovation platforms, but also offer robust support for enterprises’ future growth, helping to build a diversified and deeply empowered innovation ecosystem.

Kangqiao Healthcare Industry Facilities Platform, established in 2020, is a life sciences infrastructure investment platform under Kangqiao Capital. It is committed to providing one-stop, comprehensive infrastructure solutions for life sciences companies, helping them optimize their capital structure and improve operational efficiency, thereby enhancing corporate value.

Currently, the Kangqiao Healthcare Industry Facilities Platform has developed and operated multiple high-standard life science industrial parks in leading Chinese life sciences hubs such as Beijing, Shanghai, and Suzhou. As a leading healthcare investment platform in Asia, Kangqiao Capital will continue to partner with innovative Chinese healthcare enterprises to jointly explore the optimal pathways for corporate growth and the development of industrial ecosystems.

The Kangqiao Innovation Empowerment Series is a flagship brand initiative of the Kangqiao Medical and Health Industry Facility Platform, dedicated to building a multi-dimensional communication platform. By regularly hosting thematic seminars, industry matchmaking events, and other activities, the platform creates opportunities for in-depth exchange among medical and healthcare enterprises, facilitating effective alignment between upstream and downstream segments of the industry chain. These initiatives not only foster close collaborative relationships among enterprises but also inject new momentum into the innovative development of the medical and health sector. Looking ahead, the Kangqiao Medical and Health Industry Facility Platform will continue to uphold its philosophy of “Empowering Industry, Serving Innovation,” consistently delivering high-value empowerment activities to support medical and healthcare enterprises in achieving high-quality development.